• OFID 2018:5 (Suppl 1) • Poster Abstracts reviewed. ART regimens were assigned the following designations: contemporary firstline, contemporary non-first-line, older three-drug, two-drug, salvage, or off-ART. ART was also categorized as boosted (containing cobicistat/ritonavir) vs. unboosted, by single-tablet regimen (STR) vs. multi-tablet regimen (MTR), and frequency of dosing. Correlations between ART regimen, viral suppression, and age were analyzed.
Background. Weight gain in patients with HIV infection taking antiretroviral therapy (ART) is of great concern, given the increased risk of diabetes mellitus and cardiovascular disease in this population. Recent reports suggest that weight gain may be associated with a new ART class, the integrase strand transfer inhibitors (INSTIs) . The effect of the INSTIs elvitegravir and dolutegravir on weight and BMI in virologically suppressed patients with HIV infection has not been fully elucidated.
Methods. This retrospective observational study evaluated weight and BMI changes in aviremic HIV-infected patients who switched to an elvitegravir-or dolutegravir-containing regimen. Patients ≥18 years old on a stable ART regimen seen at the University of Utah Health Infectious Diseases Clinic between January 1, 2012 and February 28, 2017 who switched to an elvitegravir-or dolutegravir-containing regimen for at least 1 year were included. Exclusion criteria included patients with hypogonadism or a thyroid disorder, patients who received medications that impact weight (including steroids, levothyroxine, and metformin), and patients with two consecutive HIV viral load values >200 copies/mL during the study period. Body weight and BMI values collected prior to and ~1 year after the switch date were compared using paired t-tests.
Results. A total of 118 patients met study criteria and were included in the analysis. Eighty-eight (74.6%) patients were switched to a dolutegravir-containing regimen and 30 (25.4%) patients were switched to a regimen containing elvitegravir. Pre-measurements were taken 5.9 (±13.3) days prior to the switch date (range: −83, +1 days), and post-measurements were taken 310 (±56) days following the medication change (range: 186, 399 days). Weight increased on average 2.3 kg (95% CI: 1.6, 3; P < 0.001), and BMI increased on average 0.8 kg/m 2 (95% CI: 0.5, 1; P < 0.001). Conclusion. Aviremic patients with HIV gained an average of 2.3 kg ~310 days after switching to an elvitegravir-or dolutegravir-containing regimen. The average increase in BMI was 0.8 kg/m 2 . Weight gain may need to be included as a consideration when using an elvitegravir-or dolutegravir-containing regimen.
Disclosures. All authors: No reported disclosures. Background. Prior studies have reported improved adherence, persistency, virologic outcomes and lower risk of hospitalizations with single tablet (STR) vs. multi-tablet regimens (MTR) in HIV treatment. However, most studies were conducted using prescription and medical claims data limited to EFV-based therapies. In this study, we utilized EMR, prescription, and pharmacy dispensing data to assess STR and MTR adherence and persistency as observed in a network of clinical practices.
Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
Methods. Data were collected for HIV-infected patients in care at six US-based HIV treatment centers. Patients eligible for the study initiated their first ARV between January 2015 and December 2016. First ARV regimen was assigned based on absence of prior ARV prescriptions and a 30-day pre-treatment period with no ARV dispensed or for rapid starts, a high baseline viral load (≥10,000 copies/mL). Adherence was assessed using proportion of days covered (PDC). Follow-up was ≥365 days with duration capped at 365 days for persistency comparisons.
Results. A total of 1,499 patients met the criteria for the study; 66% (982/1,499) received STR and 34% (517/1,499) MTR. Top STRs were EVG/c/TDF/FTC (265/982, 27%), EVG/c/TAF/FTC (250/982, 26%), and DTG/ABC/3TC (171/982, 17%). Top MTRs were DTG + TDF/FTC (69/517, 13%), DRV + RTV + TDF/FTC (60/517, 12%), and DRV/c + TDF/FTC (40/517, 8%). Average persistency for STRs was significantly longer at 252 days vs. 233 days for MTRs (P = 0.002). Average PDC adherence rates were significantly higher for STRs at 91% vs. 83% for MTRs (P < 0.001). Within the STR group, older age was significantly associated with greater adherence (average age: 45 in 80%+ adherent group vs. 42 in <80% adherent group, P = 0.012). In both the STR and MTR groups, the percentage of black patients was significantly higher in the non-adherent group (45% in STR, 42% in MTR) compared with the adherent group (24% in STR, 32% in MTR) (P < 0.001 in STR, P = 0.027 in MTR).
Conclusion. This study of adherence with STR vs. MTR HIV therapy is novel, as it uses more currently relevant HIV regimens and was conducted utilizing EMR, prescription, and dispensing data. The results of better adherence and persistency with STR ART underscore the ongoing importance of simpler treatment for HIV care.
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